Pergolide therapy in Parkinson's disease: a double-blind, placebo-controlled study.
A double-blind, placebo-controlled study was conducted of pergolide as an adjunctive treatment to levodopa in 17 patients with advanced Parkinson's disease. There was a significant improvement (p less than 0.05) in total disability score, in gait, and in "wearing off" and "on-off" phenomena. Pergolide is a useful drug in patients with advanced Parkinson's disease.
D000328:Adult; D000368:Aged; D002986:Clinical Trials as Topic; D004311:Double-Blind Method; D004873:Ergolines / Q000627:therapeutic use*; D005684:Gait / Q000187:drug effects; D006801:Humans; D007980:Levodopa / Q000627:therapeutic use; D008875:Middle Aged; D009043:Motor Activity / Q000187:drug effects; D009069:Movement Disorders / Q000188:drug therapy; D010300:Parkinson Disease / Q000188:drug therapy*; D010479:Pergolide; D011897:Random Allocation
D004873:Ergolines; D010479:Pergolide; D007980:Levodopa